Two new mononuclear Schiff base zinc(II) complexes, [ZnClL1(N3)]·2MeOH (1) and [ZnBr2(L2)]·MeOH (2) (L1 = 4-methyl-2-[(2-piperazinium-1-ylethylimino)methyl]phenolate; L2 = 2-[(2-diethylammonioethylimino)methyl]-4-methylphenolate), have been prepared and characterized by elemental analyses, infrared and UV-vis spectroscopy, and single-cyrstal X-ray diffraction. Complex 1 crystallizes in the orthorhombic space group Pbca with unit cell dimensions a = 18.703(1), b = 11.8643(6), c = 19.081(1) Å, V = 4234.0(4) Å3, Z = 8, R1 = 0.0475, and wR2 = 0.1046. Complex 2 crystallizes in the orthorhombic space group P212121 with unit cell dimensions a = 8.863(2), b = 13.360(2), c = 17.066(3) Å, V = 2020.7(7) Å3, Z = 4, R1 = 0.0803, and wR2 = 0.1859. The Zn atoms in the complexes are four-coordinated in tetrahedral geometry by the phenolate O and imine N atoms of the Schiff base ligands, and two halide or pseudohalide ligands. Crystals of the complexes are stabilized by hydrogen bonds.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: